A Phase 2 Study of Pemetrexed and Erlotinib for Metastatic Colorectal Cancer Refractory to Standard Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Erlotinib (Primary) ; Pemetrexed (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 12 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jan 2018.
- 12 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.